Jianfeng Group Pro 2015-004 (Announcement of Jianfeng Group Providing Guarantee to Holding Subsidiary)
Release time:
2020-08-05
证券简称:尖峰集团 证券代码:600668 编号:临2015-004
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
对控股子公司提供担保的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示
● 被担保人名称:浙江尖峰药业有限公司、大冶尖峰水泥有限公司、云南尖峰水泥有限公司、金华市医药有限公司、浙江尖峰国际贸易有限公司。
●拟设定担保额度:设定担保额度6.5亿元。
● 本次担保是否有反担保:无
● 对外担保逾期的累计数量:无
一、担保情况概述
2015年4月17日,浙江尖峰集团股份有限公司召开了第九届董事会第二次会议,公司全体九名董事亲自参加了会议;符合《公司法》和《公司章程》的有关规定,所做决议合法有效。会议由蒋晓萌董事长主持,经审议与表决,以9票同意、0票反对、0票弃权审议通过了《关于为控股子公司提供担保的议案》。
二、被担保人基本情况
1、浙江尖峰药业有限公司,注册资本14907万元,其中:本公司占99.16%,注册地址:浙江省金华市婺城区白汤下线高畈段58号,主要经营:滴眼剂、滴耳剂、大容量注射剂、小容量注射剂、原料药(硫酸阿奇霉素、门冬氨酸氨氯地平、盐酸帕罗西汀)制造、销售及出口,片剂、硬胶囊剂、颗粒剂、软膏剂、滴丸剂、原料药(人工牛黄、头孢呋辛钠、加替沙星、盐酸头孢甲肟、头孢哌酮钠)制造、销售及出口;中药提取车间(限下设分支机构生产);冻干粉针剂、粉针剂(头孢菌素类)、片剂(抗肿瘤药)、原料药(甲磺酸伊马替尼)制造、销售及出口;进口生产、科研所需的原辅料;机械设备、仪器仪表及零配件等。
2、大冶尖峰水泥有限公司,注册资本2.5亿元,其中本公司占6%、本公司控股子公司浙江尖峰水泥有限公司(本公司持有95.25%)占70%。注册地址:湖北省大冶市保安镇;主要经营:水泥、水泥熟料、水泥机电设备制造及销售;建材产品销售等。
3、云南尖峰水泥有限公司,注册资本1.5亿元,其中:本公司占75%、本公司控股子公司浙江尖峰水泥有限公司(本公司持有95.25%)占25%,注册地址:云南省普洱市思茅区六顺乡思澜公路43公里处,主要经营:水泥的生产;水泥及水泥制品、建材、碎石、编织袋、水泥粉磨的销售;水泥出口贸易。
4、金华市医药有限公司,注册资本2200万元,其中:本公司控股子公司浙江尖峰药业有限公司(本公司持有99.16%)占90%、本公司占10%,注册地址:金华市环城东路1180号;主要经营:药品经营。预包装食品、危险化学品、医疗器械等。药品经营许可主要有:中成药、中药材、中药欣片、化学药制剂、化学原料药、抗生素、生化药品、生物制品、麻醉药品、精神药品等的销售。
5、浙江尖峰国际贸易有限公司,注册资本3000万元,其中:本公司占93.33%、本公司控股子公司浙江尖峰药业有限公司(本公司持有99.16%)占6.67%,注册地址:浙江金东经济开发区常春西路88号,主要经营:自营和代理各类商品及技术的进出口业务,经营进料加工和“三来一补”业务;开展对销贸易和转口贸易,保税货物和一般货物的仓储(除危险品)、医药中间体、制药设备等。
上述子公司2014年经审计的主要财务数据(单位:万元)
|
公司名称 |
总资产 |
负债总额 |
银行贷款总额 |
资产净额 |
营业收入 |
归属于母公司所有者净利润 |
|
大冶尖峰水泥有限公司 |
61798.23 |
17794.83 |
2000 |
44003.40 |
62545.78 |
11239.99 |
|
浙江尖峰药业有限公司 |
95436.34 |
62337.11 |
11900 |
33099.23 |
101124.44 |
5096.38 |
|
金华市医药有限公司 |
31480.55 |
23796.14 |
3000 |
7684.41 |
73478.07 |
650.56 |
|
云南尖峰水泥有限公司 |
53709.85 |
36057.68 |
0 |
17652.17 |
39788.44 |
3601.15 |
|
浙江尖峰国际贸易有限公司 |
8321.06 |
7267.01 |
0 |
1054.05 |
16091.27 |
448.54 |
三、提供担保的主要内容
1、对控股子公司向金融机构借款提供担保,设定如下额度:
|
被担保单位 |
设定担保额度(万元) |
|
大冶尖峰水泥有限公司 |
10000 |
|
浙江尖峰药业有限公司 |
30000 |
|
金华市医药公司 |
15000 |
|
浙江尖峰国际贸易有限公司 |
5000 |
|
云南尖峰水泥有限公司 |
5000 |
|
合计 |
65000 |
2、同意为浙江尖峰国际贸易有限公司提供担保函,为浙江尖峰国际贸易有限公司的客户在该公司存放的货物提供相应的担保。
在以上额度内的担保授权董事长分次执行。
以上事宜需提交股东大会审议。
四、董事会意见
以上被担保公司都是本公司的控股子公司,本公司能有效控制担保风险,董事会同意以上的担保。
公司三名独立董事对该事项发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
五、累计对外担保数量及逾期担保的数量
截止本公告披露日,公司及其控股子公司已批准的对外担保总额为11.5亿元,占公司2014年经审计的合并口径归属于母公司所有者权益合计的55.81%。其中,已批准的对控股子公司担保总额为50,000万元,占公司2014年经审计的合并口径归属于母公司所有者权益合计的24.26%。
截止本公告披露日,公司及其控股子公司对外担保实际余额为7.3亿元,占公司2014年经审计的合并口径归属于母公司所有者权益合计的35.42%;公司对控股子公司的担保实际余额为8000万元,占公司2014年经审计的合并口径归属于母公司所有者权益合计的3.88%。
截止本公告披露日,本公司没有逾期担保。
六、备查文件目录
1、公司第九届董事会第二次会议决议;
2、被担保人营业执照复印件;
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一五年四月二十一日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11